Vir Biotechnology ex-officer plans $315K share sale

Available on EDGAR 09/09/2026 - 10:58 AM EDT Accepted by SEC EDGAR 09/09/2026 - 10:57 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vir Biotechnology, Inc. (VIR) received a notice under Rule 144 that former officer Jason V. O'Byrne, through Fidelity Brokerage Services LLC, intends to sell 28,333 shares of common stock, expected to be issued from a stock option exercise on September 9, 2026. The filing lists an estimated aggregate sale price of $315,241.24 and states that 169,215,958 shares of common stock were outstanding as of September 9, 2026.

The notice also reports prior sales of Vir common stock for O'Byrne during the past three months, including transactions on August 21, 24, and 25, 2026.

Key Figures

Shares to be sold under Rule 144: 28,333 shares Estimated aggregate sale price: $315,241.24 Shares outstanding: 169,215,958 shares +3 more

6 metrics

Shares to be sold under Rule 144 28,333 shares Common stock planned sale by Jason V. O’Byrne from stock option exercise on September 9, 2026

Estimated aggregate sale price $315,241.24 Estimated value of the 28,333 Vir common shares to be sold

Shares outstanding 169,215,958 shares Vir Biotechnology common stock outstanding as of September 9, 2026

Sale on August 21, 2026 25,000 shares for $245,297.50 Prior three-month sale of Vir common stock by Jason V. O’Byrne

Sale on August 24, 2026 14,352 shares for $142,123.55 Prior three-month sale of Vir common stock by Jason V. O’Byrne

Sale on August 25, 2026 23,148 shares for $242,591.04 Prior three-month sale of Vir common stock by Jason V. O’Byrne

Key Terms

Rule 144, stock option exercise, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"Common | 09/09/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

attorney-in-fact regulatory

"as attorney-in-fact for Jason V. O'Byrne."

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Vir Biotechnology, Inc. (VIR)?

The filing reports that Jason V. O’Byrne, a former officer of Vir Biotechnology, plans to sell 28,333 shares of common stock under Rule 144, with shares to be issued from a stock option exercise on September 9, 2026, through Fidelity Brokerage Services LLC.

How many VIR shares does Jason V. O’Byrne plan to sell and at what estimated value?

Jason V. O’Byrne plans to sell 28,333 shares of Vir Biotechnology common stock, with an estimated aggregate sale price of $315,241.24, as disclosed in the Rule 144 notice.

What is the basis of the shares being sold in this Vir Biotechnology (VIR) Form 144?

The shares to be sold are tied to a stock option exercise, with the securities to be issued by the issuer and the transaction dated September 9, 2026, and to be settled for cash.

What prior Vir Biotechnology (VIR) stock sales by Jason V. O’Byrne are listed?

The notice lists prior sales of Vir common stock by Jason V. O’Byrne in the past three months: 25,000 shares on August 21, 2026, for $245,297.50; 14,352 shares on August 24, 2026, for $142,123.55; and 23,148 shares on August 25, 2026, for $242,591.04.

How many Vir Biotechnology (VIR) shares are reported outstanding in the notice?

The notice states that 169,215,958 shares of Vir Biotechnology common stock were outstanding as of September 9, 2026; this is a baseline figure, not the amount being offered under the Rule 144 filing.

Who is acting on behalf of Jason V. O’Byrne in the Vir Biotechnology (VIR) Form 144?

The Form 144 is signed by Jessica Spraker, a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Jason V. O’Byrne.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001871145
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vir Biotechnology, Inc.
SEC File Number	001-39083
Address of Issuer	1800 OWENS STREET SUITE 900 SAN FRANCISCO CALIFORNIA 94158
Phone	415-906-4324
Name of Person for Whose Account the Securities are To Be Sold	O'Byrne Jason
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	28333	315241.24	169215958	09/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/09/2026	Stock Option Exercise	Issuer			28333	09/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jason V. O'Byrne 1800 Owens Street Suite 900 San Francisco CA 94158	Common	08/21/2026	25000	245297.50
Jason V. O'Byrne 1800 Owens Street Suite 900 San Francisco CA 94158	Common	08/24/2026	14352	142123.55
Jason V. O'Byrne 1800 Owens Street Suite 900 San Francisco CA 94158	Common	08/25/2026	23148	242591.04

144: Remarks and Signature

Remarks
Date of Notice	09/09/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jessica Spraker, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jason V. O'Byrne.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)